1. Home
  2. IT vs PRAX Comparison

IT vs PRAX Comparison

Compare IT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gartner Inc.

IT

Gartner Inc.

HOLD

Current Price

$158.41

Market Cap

11.2B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$327.15

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IT
PRAX
Founded
1979
2015
Country
United States
United States
Employees
40
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
9.6B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
IT
PRAX
Price
$158.41
$327.15
Analyst Decision
Hold
Strong Buy
Analyst Count
10
15
Target Price
$270.44
$572.13
AVG Volume (30 Days)
2.2M
375.4K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
9.65
N/A
Revenue
$2,021,441,000.00
N/A
Revenue This Year
$3.75
N/A
Revenue Next Year
$5.15
$1,840.20
P/E Ratio
$16.22
N/A
Revenue Growth
13.30
N/A
52 Week Low
$139.18
$26.70
52 Week High
$492.06
$354.87

Technical Indicators

Market Signals
Indicator
IT
PRAX
Relative Strength Index (RSI) 37.52 53.37
Support Level $139.18 $290.36
Resistance Level $164.47 N/A
Average True Range (ATR) 7.05 18.77
MACD 2.77 -1.12
Stochastic Oscillator 70.48 55.40

Price Performance

Historical Comparison
IT
PRAX

About IT Gartner Inc.

Gartner provides independent research and analysis on information technology for chief information officers and other business executives who help plan companies' IT budgets. Its flagship Magic Quadrant reports inform many enterprises of their IT procurement decisions. Gartner also provides consulting services and holds some of the largest conferences in the IT industry. Around 80% of Gartner's revenue is generated from industry research.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: